ImmunityBio (IBRX) Assets Average (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Assets Average data on file, last reported at $574.3 million in Q1 2026.

• On a quarterly basis, Assets Average rose 67.26% year-over-year to $574.3 million in Q1 2026; TTM through Mar 2026 was $574.3 million, a 67.26% increase from a year earlier, with the FY2025 full-year figure at $442.4 million, changed 0.29% from the prior year.
• Assets Average for Q1 2026 stood at $574.3 million, up from $510.4 million in the prior quarter.
• Over the last five years, Assets Average for IBRX reached as high as $574.3 million in Q1 2026 and fell as low as $317.3 million in Q2 2023.
• Historically, Assets Average has averaged $404.2 million across 5 years, with a median of $373.8 million in 2024.
• Across the five-year window, Assets Average surged 99.28% in 2022 and declined 24.13% in 2025, its largest moves.
• Year by year, Assets Average stood at $357.6 million in 2022, then surged by 30.98% to $468.4 million in 2023, then slipped by 20.21% to $373.8 million in 2024, then surged by 36.57% to $510.4 million in 2025, then rose by 12.5% to $574.3 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $574.3 million in Q1 2026, $510.4 million in Q4 2025, and $460.5 million in Q3 2025.